Quality Assurance (QA) – Page 4

Quality event trending ignored during internal audit follow-up – FDA/MHRA inspector questions to prepare for

The first step in addressing quality event trending is the identification of symptoms or signals that indicate a potential issue. Common signals may include:Click to read the full article.

Batch disposition delayed during internal audit follow-up – FDA/MHRA inspector questions to prepare for

Identifying symptoms and signals that denote a delay in batch disposition is crucial in the early stages of an investigation. Common symptoms include:Click to read the full article.

Audit finding not escalated during management review – FDA/MHRA inspector questions to prepare for

Recognizing the symptoms or signals that indicate an audit finding has not been escalated is the first step in the investigation. Common signs include:Click to read the full article.

Inadequate risk assessment during batch release decision – regulatory expectation gap and how to fix it

Recognizing symptoms or signals indicative of inadequate risk assessment during batch release decisions is crucial for maintaining compliance and product quality. Here are common indicators to monitor:Click to read the…

Inconsistent SOP interpretation during QA review – regulatory expectation gap and how to fix it

The first step in addressing inconsistent SOP interpretation involves recognizing the symptoms or signals that may indicate such issues. Common observations include:Click to read the full article.

Audit finding not escalated during management review – GDP documentation do’s and don’ts

Recognizing the symptoms of audit findings not being escalated during management reviews is crucial for timely intervention. Here are some common signals observed in the lab and manufacturing floor:Click to…

Quality event trending ignored during batch release decision – GDP documentation do’s and don’ts

In any manufacturing environment, recognizing the signs of overlooked quality event trends is crucial. Symptoms may manifest as:Click to read the full article.

Quality event trending ignored during regulatory inspection readiness – FDA/MHRA inspector questions to prepare for

Recognizing early symptoms or signals of quality events is fundamental for timely intervention and effective deviation investigations. Symptoms can manifest in various forms, including:Click to read the full article.

Training evidence weak during regulatory inspection readiness – GDP documentation do’s and don’ts

Addressing Weak Training Evidence During Regulatory Inspections in Pharma In the pharmaceutical industry, the robustness of training documentation is paramount for compliance during regulatory inspections. Weak training evidence can lead…

Supplier deviation not assessed during QA review – GDP documentation do’s and don’ts

Assessing Supplier Deviations During QA Reviews: An Investigation Guide In pharmaceutical manufacturing, the failure to adequately assess supplier deviations during Quality Assurance (QA) reviews can pose significant risks to product…

Training evidence weak during batch release decision – FDA/MHRA inspector questions to prepare for

Identifying symptoms of weak training evidence is crucial to trigger prompt investigations. Common signals include:Click to read the full article.

Deviation closed without effectiveness check during internal audit follow-up – regulatory expectation gap and how to fix it

Identifying the signs that a deviation was closed without proper validation is crucial for early intervention. In pharmaceutical operations, several indicators may point to this issue:Click to read the full…